ResMed Inc. (ASX: RMD) shares have hit a 52-week low, but the valuation, earnings growth, and sleep health opportunity look ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The popular research ...

SAN DIEGO – Masks and accessories were the standout growth category for Resmed in the second quarter of its fiscal year 2026, with the company reporting a 16% increase in revenue in the United States, ...

Expanding from its core sleep apnoea franchise, Resmed has paid $500 million to treat the common restless leg syndrome.

Resmed Inc () has held its Q3 earnings call. Read on for the main highlights of the call. Claim 55% Off TipRanks. Unlock hedge fund-level data and powerful investing tools for sma ...

ResMed (NYSE:RMD) reported third-quarter fiscal 2026 results highlighted by revenue growth, gross margin expansion, and higher non-GAAP earnings per share, while also announcing a CFO transition and a ...

Medical device company ResMed (NYSE:RMD) reported Q1 CY2026 results exceeding the market’s revenue expectations, with sales ...

ResMed shares (ASX: RMD) opened May at a fresh two year low of A$28.40 despite delivering third-quarter results that beat analyst expectations across revenue, earnings, and margins, underscoring a ...

ResMed reported 11% growth in third quarter revenue to USD1.4 billion ($1.9 billion), up from USD1.2 billion in the prior ...

Resmed said its Chief Financial Officer will retire in May and announced plans to acquire a startup with an FDA de novo ...

Although the revenue and EPS for ResMed (RMD) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street ...

Revenue increased by 11% to $1.4 billion; up 8% on a constant currency basis GAAP gross margin up 290 bps to 62.2%; non-GAAP gross margin up 290 ...